Zobrazeno 1 - 10
of 26
pro vyhledávání: '"April F Mohanty"'
Autor:
Mary Jo Pugh, Jolie N Haun, P Jon White, Gerald Cochran, April F Mohanty, Lisa M McAndrew, Adam J Gordon, Richard E Nelson, Megan E Vanneman, Diana E Naranjo, Rachel C Benzinger, Audrey L Jones, Jacob Kean, Susan L Zickmund, Angela Fagerlin
Publikováno v:
JMIR Research Protocols, Vol 13, p e59830 (2024)
BackgroundAll federal agencies are required to support appropriation requests with evidence and evaluation (US Public Law 115-435; the Evidence Act). The StrAtegic PoLicy EvIdence-Based Evaluation CeNTer (SALIENT) is 1 of 6 centers that help the Depa
Externí odkaz:
https://doaj.org/article/fee90a16a0554c1681b96045e4864644
Autor:
Catherine G Derington, Jordana B Cohen, April F Mohanty, Tom H Greene, James Cook, Jian Ying, Guo Wei, Jennifer S Herrick, Vanessa W Stevens, Barbara E Jones, Libo Wang, Alexander R Zheutlin, Andrew M South, Thomas C Hanff, Steven M Smith, Rhonda M Cooper-DeHoff, Jordan B King, G Caleb Alexander, Dan R Berlowitz, Faraz S Ahmad, M Jason Penrod, Rachel Hess, Molly B Conroy, James C Fang, Michael A Rubin, Srinivasan Beddhu, Alfred K Cheung, Weiming Xian, William S Weintraub, Adam P Bress
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248080 (2021)
BackgroundAngiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may positively or negatively impact outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the associa
Externí odkaz:
https://doaj.org/article/9f95d8c5dcd04d9b8f8dc9e9a0d7a189
Autor:
April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 20 (2021)
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sac
Externí odkaz:
https://doaj.org/article/b3e4d96313984c458e4300e40728aa41
Publikováno v:
The journal of maternal-fetalneonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 35(25)
BACKGROUND Maternal cadmium (Cd) burden has been associated with offspring birth size measures, yet associations of placental Cd with birth size are less clear. Further, the role of genetics in these associations has not been examined. We investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dda4316a4fbf27998f565c8f5c248a78
https://pubmed.ncbi.nlm.nih.gov/34666587
https://pubmed.ncbi.nlm.nih.gov/34666587
Autor:
Patricia A. Russo, Adam P. Bress, Jennifer S. Herrick, John A. Dodson, Olga V. Patterson, James Cook, Engels N. Obi, Tao He, Jordan B. King, James C. Fang, April F. Mohanty, Emily B. Levitan, Patrick R. Alba, Michelle Choi, Orly Vardeny
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69df28aaec81f60f48e4ad75bc1d7286
https://doi.org/10.1161/jaha.120.020474
https://doi.org/10.1161/jaha.120.020474
Autor:
Morgan M. Millar, Daichi Shimbo, April F. Mohanty, Keith C. Ferdinand, Monika M. Safford, Adam P. Bress, Paul Muntner, John Stuligross, Kristi Reynolds, Kolawole S. Okuyemi, Valy Fontil, Jordana B. Cohen, Molly B. Conroy, Michael Rakotz, Karen L. Margolis, Beverly B. Green, David Edmund Anstey
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 11 (2021)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 11 (2021)
The COVID‐19 pandemic is a public health crisis, having killed more than 514 000 US adults as of March 2, 2021. COVID‐19 mitigation strategies have unintended consequences on managing chronic conditions such as hypertension, a leading cause of ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae22f755b6e55facf636302086ae5560
http://europepmc.org/articles/PMC8483507
http://europepmc.org/articles/PMC8483507
Autor:
Jordana B. Cohen, Jian Ying, Tom Greene, Catherine G. Derington, James L. Cook, April F. Mohanty
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251897 (2021)
[This corrects the article DOI: 10.1371/journal.pone.0248080.].
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07abaaaea5d75fd5bb669333233cc606
https://doaj.org/article/accbc489f1bd46b7907f93af4e84091f
https://doaj.org/article/accbc489f1bd46b7907f93af4e84091f
Autor:
Patrick R. Alba, Tao He, Michelle Choi, John A. Dodson, Patricia A. Russo, April F. Mohanty, Emily B. Levitan, Orly Vardeny, Jordan B. King, Adam P. Bress, Joanne LaFleur, Olga V. Patterson
Publikováno v:
Circulation. Heart failure. 12(11)
Background: US guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker), be switched to sacubitril/valsartan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc3c53594ab510234d0585c141078dd
https://pubmed.ncbi.nlm.nih.gov/31718321
https://pubmed.ncbi.nlm.nih.gov/31718321
Autor:
Libo Wang, M. Jason Penrod, James L. Cook, Weiming Xian, Alfred K. Cheung, Jordana B. Cohen, Guo Wei, Vanessa W. Stevens, Alexander R. Zheutlin, Jennifer S. Herrick, Molly B. Conroy, Rhonda M. Cooper-DeHoff, April F. Mohanty, Andrew M South, Faraz S. Ahmad, Dan R. Berlowitz, G. Caleb Alexander, Jian Ying, Michael Rubin, Barbara E. Jones, Thomas C. Hanff, Tom Greene, Rachel Hess, Catherine G. Derington, Adam P. Bress, Srinivasan Beddhu, Jordan B. King, James C. Fang, William S. Weintraub, Steven M. Smith
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 4, p e0248080 (2021)
PLoS ONE, Vol 16, Iss 4, p e0248080 (2021)
Background Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may positively or negatively impact outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25986a1e745da76329e6cc3f07e205d7
https://doi.org/10.1371/journal.pone.0248080
https://doi.org/10.1371/journal.pone.0248080
Autor:
Robert T. Rolfs, Jacob Crook, Christina A. Porucznik, Brian C. Sauer, Erin M. Johnson, April F. Mohanty
Publikováno v:
Health Informatics Journal. 23:35-43
Utah’s Controlled Substance Database prescription registry does not include master identifiers to link records for individual patients. We describe and evaluate a linkage protocol for Utah’s Controlled Substance Database. Prescriptions (N = 22,40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b391f713f96d793c492d16abf50a4f5
https://doi.org/10.1177/1460458215618520
https://doi.org/10.1177/1460458215618520